EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Tetrabenazine, a vesicular monoamine transporter 2 inhibitor, inhibits vesicular storage capacity and release of monoamine transmitters in mouse brain tissue

Pál Tod iD, Anita Varga iD, Viktor Román iD, Balázs Lendvai iD, Roland Pálkovács iD, Beáta Sperlágh iD, E Sylvester Vizi iD

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.17348 ↗

At a glance

Journal article in British Journal of Pharmacology, 2024. Written by Pál Tod and 6 co-authors. Institution: Laboratory of Molecular Pharmacology, HUN-REN Institute of Experimental Medicine, Budapest, Hungary. Major MEDLINE topics: Tetrabenazine, Vesicular Monoamine Transport Proteins. Cited 5 times so far (Crossref); 62 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Recovery and Resilience Facility of the European Union within the framework of Programme Széchenyi Plan Plus.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Tetrabenazine (TBZ), used for treating hyperkinetic disorders, inhibits vesicular monoamine transporter‐2 (VMAT‐2), which sequesters monoamines into vesicles for exocytosis. However, our knowledge of the effect of TBZ on monoaminergic transmission is limited. Herein, we provide neurochemical evidence regarding the effect of VMAT‐2 inhibition on vesicular neurotransmitter release from the prefrontal cortex (PFC) and striatum (STR) (brain regions involved in characteristic TBZ treatment side effects). The interaction between TBZ and MDMA was also assessed regarding motor behaviour in mice. Experimental Approach Vesicular storage capacity and release of [ 3 H]‐noradrenaline ([ 3 H]‐NA), [ 3 H]‐dopamine ([ 3 H]‐DA), [ 3 H]‐serotonin ([ 3 H]‐5‐HT), and [ 3 H]‐acetylcholine ([ 3 H]‐ACh) was studied in mouse PFC and STR ex vivo slice preparations using electrical field stimulation. Additionally, locomotor activity was assessed in vehicle‐treated mice and compared with that of MDMA, TBZ, and co‐administered animals (n = 6) using the LABORAS system. Key Results TBZ lowered the storage capacity and inhibited the vesicular release of [ 3 H]‐NA and [ 3 H]‐DA from the PFC, and [ 3 H]‐DA and [ 3 H]‐5‐HT from the STR in a concentration‐dependent manner. Unlike vesamicol (vesicular ACh uptake inhibitor), TBZ failed to inhibit the vesicular release of [ 3 H]‐ACh from the PFC. When the vesicular storage of the investigated monoamines was inhibited by TBZ in the PFC and STR, MDMA induced the release of transmitters through transporter reversal; MDMA dose dependently increased locomotor activity in vivo. Conclusion and Implications Our observations provide neurochemical evidence explaining the mechanism of VMAT‐2 inhibitors in the brain and support the involvement of dopaminergic and noradrenergic transmission in hyperkinetic movement disorders.

Subjects

MeSH terms (MEDLINE)

TetrabenazineVesicular Monoamine Transport ProteinsAnimalsMaleMiceMotor ActivityDopamineN-Methyl-3,4-methylenedioxyamphetaminePrefrontal CortexAdrenergic Uptake InhibitorsBiogenic MonoaminesCorpus StriatumNorepinephrineAcetylcholineSynaptic VesiclesSerotonin

Author keywords

acetylcholineexocytosishyperkinesismouse modeltetrabenazinevesicular monoamine transport proteins

Substances

TetrabenazineVesicular Monoamine Transport ProteinsSlc18a2 protein, mouseDopamineN-Methyl-3,4-methylenedioxyamphetamineAdrenergic Uptake InhibitorsBiogenic MonoaminesNorepinephrineAcetylcholineSerotonin

Authors and institutions

  • Laboratory of Molecular Pharmacology, HUN-REN Institute of Experimental Medicine, Budapest, Hungary.
  • Pharmacology and Drug Safety Research, Gedeon Richter Plc, Budapest, Hungary.
  • Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.

ORCID profiles: Pál Tod, Anita Varga, Viktor Román, Balázs Lendvai, Roland Pálkovács, Beáta Sperlágh, E Sylvester Vizi

Funding

  • Recovery and Resilience Facility of the European Union within the framework of Programme Széchenyi Plan Plus

Cite

APA

Tod, P., Varga, A., Román, V., Lendvai, B., Pálkovács, R., Sperlágh, B., & Vizi, E. S. (2024). Tetrabenazine, a vesicular monoamine transporter 2 inhibitor, inhibits vesicular storage capacity and release of monoamine transmitters in mouse brain tissue. British Journal of Pharmacology. https://doi.org/10.1111/bph.17348

Vancouver

Tod P, Varga A, Román V, Lendvai B, Pálkovács R, Sperlágh B, et al. Tetrabenazine, a vesicular monoamine transporter 2 inhibitor, inhibits vesicular storage capacity and release of monoamine transmitters in mouse brain tissue. British Journal of Pharmacology. 2024. doi:10.1111/bph.17348

BibTeX
@article{Tod2024,
  author = {Tod, Pál and Varga, Anita and Román, Viktor and Lendvai, Balázs and Pálkovács, Roland and Sperlágh, Beáta and Vizi, E Sylvester},
  title = {Tetrabenazine, a vesicular monoamine transporter 2 inhibitor, inhibits vesicular storage capacity and release of monoamine transmitters in mouse brain tissue},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.17348}
}
Start for free →